Breast Cancer Research and Treatment

, Volume 2, Issue 2, pp 163–169

Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer

  • Aman U. Buzdar
  • Terry L. Smith
  • Kimberly C. Powell
  • George R. Blumenschein
  • Edmund A. Gehan
Report

DOI: 10.1007/BF01806452

Cite this article as:
Buzdar, A.U., Smith, T.L., Powell, K.C. et al. Breast Cancer Res Tr (1982) 2: 163. doi:10.1007/BF01806452

Summary

Four hundred and sixty patients with stage II or III breast cancer following regional therapy were treated with an adjuvant combination chemotherapy consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The relationship between the length of disease-free survival and length of delays in initiation of chemotherapy after surgery was evaluated. Patients were divided into four subgroups according to the length of delay in initiation of chemotherapy (< 10 weeks, 10–13, 14–17, and ≥ 18 weeks). Overall four year diseasefree survival was 64%, 68%, 60%, and 63% for patient groups with delays of < 10 weeks, 10–13, 14–17, or ≥ 18 weeks respectively (p = 0.39). There was no trend for longer delay in treatment to be associated with shorter disease-free survival, except in poor prognosis patients.

Keywords

adjuvant therapy delay breast cancer disease-free survival FAC 

Copyright information

© Martinus Nijhoff Publishers 1982

Authors and Affiliations

  • Aman U. Buzdar
    • 1
  • Terry L. Smith
    • 2
  • Kimberly C. Powell
    • 1
  • George R. Blumenschein
    • 1
  • Edmund A. Gehan
    • 2
  1. 1.Medical Breast Service-Department of MedicineThe University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor InstituteHoustonUSA
  2. 2.Department of BiomathematicsThe University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor InstituteHoustonUSA